PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy

  • STATUS
    Recruiting
  • participants needed
    48
  • sponsor
    University Hospital, Brest
Send
Updated on 16 February 2024
See if I qualify
pembrolizumab
nivolumab
pet/ct scan
metastatic melanoma
melanoma
dynamic acquisition

Summary

The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with immune checkpoint inhibitors (ICI)to predict the progression of the disease..

Details
Condition Metastatic Melanoma
Age 18years - 100years
Treatment value of 4D body-to-whole dynamic acquisition in FDG
Clinical Study IdentifierNCT04272658
SponsorUniversity Hospital, Brest
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patient old 18 years
With metastatic melanoma
Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
Having formulated a non-opposition

Exclusion Criteria

\- Minor patient < 18 years
Pregnancy or breastfeeding
Other type of tumor than metastatic melanoma
Non-eligibility for the examination
Refusal of participation
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

pembrolizumab
nivolumab
pet/ct scan
metastatic melanoma
melanoma
dynamic acquisition

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.